Literature DB >> 15466929

Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.

Ton Lisman1, Philip G de Groot, Joost C M Meijers, Frits R Rosendaal.   

Abstract

The role of the fibrinolytic system in the development of deep vein thrombosis (DVT) is unclear. We determined the plasma fibrinolytic potential of patients enrolled in the Leiden Thrombophilia Study (LETS), a population-based case-control study on risk factors for DVT. Plasma fibrinolytic potential was determined in 421 patients and 469 control subjects by means of a tissue factor-induced and tissue-type plasminogen activator (tPA)-induced clot lysis assay. Using clot lysis times above the 70th, 80th, 90th, 95th, and 99th percentiles of the values found in control subjects as cut-off levels, we found a dose-dependent increase in risk for DVT in patients with hypofibrinolysis (odds ratios of 1.4, 1.6, 1.9, 2.1, and 2.2, respectively). This indicates a 2-fold increased risk of DVT in subjects with clot lysis times above the 90th percentile. The risk increase was not affected by age or sex (adjusted odds ratio for 90th percentile, 2.0), and after correction for all possible confounders (age, sex, and levels of procoagulant proteins shown to associate with clot lysis times in the control population), the risk estimate was marginally reduced (odds ratio, 1.6 for 90th percentile). Taken together, these results indicate that plasma hypofibrinolysis constitutes a risk factor for venous thrombosis, with a doubling of the risk at clot lysis times that are present in 10% of the population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466929     DOI: 10.1182/blood-2004-08-3253

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Effects of cryoablation and radiofrequency ablation on endothelial and blood clotting activation.

Authors:  Paolo Pieragnoli; Anna Maria Gori; Giuseppe Ricciardi; Gianmarco Carrassa; Luca Checchi; Antonio Michelucci; Raffaella Priora; Anna Paola Cellai; Rossella Marcucci; Luigi Padeletti; Rosanna Abbate
Journal:  Intern Emerg Med       Date:  2014-06-21       Impact factor: 3.397

Review 2.  Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.

Authors:  Keattiyoat Wattanakit; Mary Cushman
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

Review 3.  Fibrinogen and red blood cells in venous thrombosis.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Alisa S Wolberg
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

4.  Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred.

Authors:  M E Meltzer; S J Hasstedt; C Y Vossen; P W Callas; Ph G DE Groot; F R Rosendaal; T Lisman; E G Bovill
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 5.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

6.  Age and aerobic training status effects on plasma and skeletal muscle tPA and PAI-1.

Authors:  Ryan M Francis; Christine L Romeyn; Adam M Coughlin; Paul R Nagelkirk; Christopher J Womack; Jeffrey T Lemmer
Journal:  Eur J Appl Physiol       Date:  2014-03-07       Impact factor: 3.078

7.  Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.

Authors:  Chiné Pieterse; Rudolph Schutte; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

8.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.

Authors:  Zurina Romay-Penabad; Maria Guadalupe Montiel-Manzano; Tuya Shilagard; Elizabeth Papalardo; Gracie Vargas; Arun B Deora; Michael Wang; Andrew T Jacovina; Ethel Garcia-Latorre; Elba Reyes-Maldonado; Katherine A Hajjar; Silvia S Pierangeli
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

9.  Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity.

Authors:  Anna Paola Cellai; Donatella Lami; Emilia Antonucci; Agatina Alessandrello Liotta; Angela Rogolino; Sandra Fedi; Claudia Fiorillo; Matteo Becatti; Caterina Cenci; Rossella Marcucci; Rosanna Abbate; Domenico Prisco
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

10.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.